Рекомендации Американской ассоциации сердца / Американского колледжа кардиологии 2020 года по диагностике и лечению пациентов с гипертрофической кардиомиопатией: что нового?
Автор: Будагаев Сергей Александрович, Афанасьев А.В., Богачев-прокофьев А.В., Залесов А.С., Овчаров М.А.
Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin
Рубрика: Рекомендации
Статья в выпуске: 2 т.25, 2021 года.
Бесплатный доступ
22 декабря 2020 г. в журнале Circulation опубликовали новые рекомендации Американской ассоциации сердца / Американского колледжа кардиологии по диагностике и лечению пациентов с гипертрофической кардиомиопатией. Наиболее важные изменения коснулись фармакологических и инвазивных методов лечения симптоматических пациентов с обструкцией выходного отдела левого желудочка. С учетом последних клинических исследований расширены показания к инвазивным методам лечения: септальной миоэктомии и спиртовой септальной аблации. Отдельный раздел посвящен тактике ведения больных необструктивной гипертрофической кардиомиопатией с сохраненной фракцией выброса левого желудочка. Изменены рекомендации для пациентов с гипертрофической кардиомиопатией и фибрилляцией предсердий, желудочковыми аритмиями, выраженной сердечной недостаточностью.
Гипертрофическая кардиомиопатия, клинические рекомендации
Короткий адрес: https://sciup.org/142230782
IDR: 142230782 | DOI: 10.21688/1681-3472-2021-2-108-115
Список литературы Рекомендации Американской ассоциации сердца / Американского колледжа кардиологии 2020 года по диагностике и лечению пациентов с гипертрофической кардиомиопатией: что нового?
- Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P., Evanovich L.L., Hung J., Joglar J.A., Kantor P., Kimmelstiel C., Kittleson M.,Link M.S., Maron M.S., Martinez M.W., Miyake C.Y., Schaff H.V., Semsarian C., Sorajja P. 2020 AHA / ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e533-e557. PMID: 33215938. https://doi. org/10.1161/CIR.0000000000000938
- Authors / Task Force members, Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., Hagege A.A., Lafont A., Limongelli G., Mahrholdt H., McKenna W.J., Mogensen J., Nihoyannopoulos P., Nistri S., Pieper P.G., Pieske B., Rapezzi C., Rutten F.H., Tillmanns C., Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. PMID: 25173338. https://doi. org/10.1093/eurheartj/ehu284
- Ho C.Y., Mealiffe M.E., Bach R.G., Bhattacharya M., Choudhury L., Edelberg J.M., Hegde S.M., Jacoby D., Lakdawala N.K., Lester S.J., MaY., Marian A.J., Nagueh S.F., Owens A., Rader F., Saberi S., Sehnert A.J., Sherrid M.V., Solomon S.D., Wang A., Wever-Pinzon O., Wong T.C., Heitner S.B. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21 ):2649-2660. PMID: 32466879. https://doi. org/10.1016/i.iacc.2020.03.064
- Olivotto I., Oreziak A., Barriales-Villa R., Abraham T.P., Masri A., Garcia-Pavia P., Saberi S., Lakdawala N.K., Wheeler M.T., Owens A., Kubanek M., Wojakowski W., Jensen M.K., Gimeno-Blanes J., Afshar K., Myers J., Hegde S.M., Solomon S.D., Sehnert A.J., Zhang D., Li W., Bhattacharya M., Edelberg J.M., Waldman C.B., Lester S.J., Wang A., Ho C.Y., Jacoby D., EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. PMID: 32871100. https://doi. org/10.1016/S0140-6736(20)31792-X
- Maron B.J., Rowin E.J., Casey S.A., Maron M.S. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol. 2016;1(1):98-105. PMID: 27437663. https:// doi.org/10.1001/jamacardio.2015.0354
- Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., Naidu S.S., Nishimura R.A., Ommen S.R., Rakowski H., Seidman C.E., Towbin J.A., Udelson J.E., Yancy C.W.; American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF / AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation. 2011 ;124(24):e783-831. PMID: 22068434. https://doi.org/10.1161/CIR.0b013e318223e2bd
- Holst K.A., Hanson K.T., Ommen S.R., Nishimura R.A., Habermann E.B., Schaff H.V. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery. Mayo Clin Proc. 2019;94(1):66-73. PMID: 30611455. https://doi.org/10.1016/i. mayocp.2018.07.022
- Hong J.H., Schaff H.V., Nishimura R.A., Abel M.D., Dearani J.A., Li Z., Ommen S.R. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016;68(14):1497-1504. PMID: 27687190. https://doi.org/10.1016/uacc.2016.07.735
- Pelliccia F., Pasceri V., Limongelli G., Autore C., Basso C., Corrado D., Imazio M., Rapezzi C., Sinagra G., Mercuro G., Working Group on Cardiomyopathies and Pericardial Diseases of the Italian Society of Cardiology. Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2017;243:379-384. PMID: 28747036. https://doi.org/10.1016/Uicard.2017.06.071
- Axelsson A., Iversen K., Vejlstrup N., Ho C., Norsk J., Langhoff L., Ahtarovski K., Corell P., Havndrup O., Jensen M., Bundgaard H. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-131. PMID: 25533774. https://doi.org/10.1016/ S2213-8587(14)70241-4
- Nguyen A., Schaff H.V., Nishimura R.A., Geske J.B., Dearani J.A., King K.S., Ommen S.R. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. J Thorac Cardiovasc Surg. 2019;159(1 ):145-152. PMID: 31053431. https://doi.org/10.1016/Mtcvs.2019.03.088
- Van Gelder I.C., Healey J.S., Crijns H.J.G.M., Wang J., Hohnloser S.H., Gold M.R., Capucci A., Lau Ch.-P., Morillo C.A., Hobbelt A.H., Rienstra M., Connolly S.J. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17):1339-1344. PMID: 28329139. https://doi. org/10.1093/eurheartj/ehx042
- January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. Jr, Conti J.B., Ellinor P.T., Ezekowitz M.D., Field M.E., Murray K.T., Sacco R.L., Stevenson W.G., Tchou P.J., Tracy C.M., Yancy C.W.; ACC / AHA Task Force Members. 2014 AHA / ACC / HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267. PMID: 24682347; PMCID: PMC4676081. https://doi.org/10.1161/ CIR.0000000000000041
- Federal Motor Carrier Safety Administration (FMCSA), DOT. Process for Department of Veterans Affairs (VA) physicians to be added to the National Registry of Certified Medical Examiners. Final rule. Fed Regist. 2018;83(112):26846-26884. PMID: 30019876.
- Providencia R., Elliott P., Patel K., McCready J., Babu G., Srinivasan N., Bronis K., Papageorgiou N., Chow A., Rowland E., Lowe M., Segal O.R., Lambiase P.D. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart. 2016;102(19):1533-1543. PMID: 27234160. https://doi. org/10.1136/heartjnl-2016-309406
- Bogachev-Prokophiev A.V., Afanasyev A.V., Zheleznev S.I., Pivkin A.N., Fomenko M.S., Sharifulin R.M., Karaskov A.M. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(4):1536-1542.e2. PMID: 28947201. https://doi.org/10.1016/utcvs.2017.08.063
- Connolly S.J., Dorian P., Roberts R.S., Gent M., Bailin S., Fain E.S., Thorpe K., Champagne J., Talajic M., Coutu B., Gronefeld G.C., Hohnloser S.H.; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-171. PMID: 16403928. https://doi.org/10.1001/jama.295.2.165
- Baquero G.A., Banchs J.E., Depalma S., Young S.K., Penny-Peterson E.D., Samii S.M., Wolbrette D.L., Naccarelli G.V., Gonzalez M.D. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol. 2012;23(3):296-301. PMID: 21955243. https://doi.org/10.1111/i.1540-8167.2011.02183.x
- Santangeli P., Muser D., Maeda Sh., Filtz A., Zado E.S., Frankel D.S., Dixit S., Epstein A.E., Callans D.J., Marchlinski F.E. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13(7):1552-1559. PMID: 26961297. https://doi. org/10.1016/i.hrthm.2016.03.004
- Maron B.J., Shen W.K., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Bardy G.H., Favale S., Rea R.F., Boriani G., Estes N.A. 3rd, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342(6):365-373. PMID: 10666426. https://doi.org/10.1056/NEJM200002103420601
- Igarashi M., Nogami A., Kurosaki K., Hanaki Y., Komatsu Y., Fukamizu S., Morishima I., Kaitani K., Nishiuchi S., Talib A.K., Machino T., Kuroki K., Yamasaki H., Murakoshi N., Sekiguchi Y., Kuga K., Aonuma K. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol. 2018;4(3):339-350. PMID: 30089559. https://doi.org/10.1016/Macep.2017.12.020
- Dukkipati S.R., d'Avila A., Soejima K., Bala R., Inada K., Singh Sh., Stevenson W.G., Marchlinski F.E., Reddy V.Y. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(2):185-194. PMID: 21270104. https://doi.org/10.1161/ CIRCEP.110.957290
- Maron B.J., Ommen S.R., Semsarian C., Spirito P., Olivotto I., Maron M.S. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83-99. PMID: 24998133. https://doi. org/10.1016/j.jacc.2014.05.003
- Maron B.J. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655-668. PMID: 30110588. https://doi.org/10.1056/NEJMra1710575
- Topilsky Y., Pereira N.L., Shah D.K., Boilson B., Schirger J.A., Kushwaha S.S., Joyce L.D., Park S.J. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011;4(3):266-275. PMID: 21303989. https://doi.org/10.1161/aRCHEARTFAILURE.110.959288
- Hebl V.B., Miranda W.R., Ong K.C., Hodge D.O., Bos J.M., Gentile F., Klarich K.W., Nishimura R.A., Ackerman M.J., Gersh B.J., Ommen S.R., Geske J.B. The natural history of nonobstructive hypertrophic cardiomyopathy. Mayo Clin Proc. 2016;91(3):279-287. PMID: 26944240. https://doi.org/10.1016/_i.mayocp.2016.01.002